[1] Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36：a physiological incretin in man[J]. The Lancet, 1987, 2（4）：1300-1303.
[2] Vahl TP, Paty BW, Fuller BD, et al. Effects of GLP-1-（7-36）NH2, GLP-1-（7-37）, and GLP-1-（9-36）NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans[J]. Clinical Endocrinology Metabolism, 2003, 88（4）：1772-1779.
[3] Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding[J]. Nature, 1996, 379（4）：69-72.
[4] Ahrén B, Winzell MS, Wierup N, et al. Hughes, DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 respo-nses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide[J]. Regulatory Peptides, 2007, 143（1-3）：97-103.
[5] Burcelin R, Dejager S. GLP-1：what is known, new and controversial in 2010[J]. Diabetes Metab, 2010, 36（6）：503-509.
[6] Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo[J]. Clinical Endocrinology Metabolism, 1995, 80（3）：952-957.
[7] Dou WF, Lei JY, Zhang LF, et al. Expression, purification, and characterization of recombinant human serum albumin fusion protein with two human glucagon-like peptide-1 mutants in Pichia pastoris[J]. Protein Expression and Purification, 2008, 61（1）：45-49.
[8] Wu YL, Huang J, Xu J, et al. Addition of a cysteine to glucagon-like peptide-1（GLP-1）conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo[J]. Regulatory Peptides, 2010, 164：83-89.
[9] John H, Maronde E, Forssmann WG, et al. N-terminal acetylation protects glucagon-like peptide GLP-1-（7-34）-amide from DPP-IV-mediated degradation retaining cAMP and insulin-releasing capacity[J]. Eur J Med Res, 2008, 13：73-78.
[10] Zhang QF, Ding F, Xue XY, et al. Changing the N-terminal sequence protects recombinant Plasmodium falciparum circumsporozoite protein from degradation in Pichia pastoris[J]. Applied Genetics and Molecular Biotechnology, 2008, 78：139-145.
[11] Joan LC, William WW, See X, et al. Condensed protocol for competent cell preparation and transformation of the methylotrophic yeast Pichia pastoris[J]. Biotechniques, 2005, 38（1）：44-48.
[12] Chen J, Bai G, Cao Y, et al. One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique[J]. Biosci Biotechnol Biochem, 2007, 71（11）：2655-2662.
[13] Ueda T, Ito T, Tomita K, et al. Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution[J]. Bioorg Med Chem Lett, 2010, 20（15）：4631-4634. |
